Atossa Therapeutics, Inc.ATOS

Atossa Therapeutics closed a registered direct offering on 12 June 2026, netting up to $16.5 million in gross proceeds to fund its (Z)-endoxifen SERM programme. The cash is earmarked for continued US and international regulatory filings, plus the EVANGELINE Phase 2 trial that is meant to show whether a next-generation selective estrogen receptor modulator can relative strength older drugs in breast-cancer patients with ESR1 mutations. The company’s own investor site lists the raise as “closed,” but the filing makes clear the money is contingent on future tranches, so the full $16.5 million may not land in one go. (source: ATOS 424B5, https://www.sec.gov/Archives/edgar/data/1488039/000119312526268597/project_rdo_june_2026_-_.htm)

Atossa Therapeutics is a clinical-stage oncology outfit chasing unmet needs in breast cancer with a single pipeline asset: (Z)-endoxifen, a “next-generation SERM” engineered to deliver roughly 100-times the potency of existing treatments while promising a more tolerable side-effect profile. The company’s science pages trumpet its ambition to transform care, but the stark truth is there are no marketed products today, no revenue line, and no guarantee that the ASCO 2026 abstracts-which highlight activity in ESR1-mutant tumours-will translate into a pivotal readout. The website’s patient guidance not to send personal data is the clearest admission yet that the organisation is still building the operational plumbing around its trials. (source: Clinical Trials, https://www.atossatherapeutics.com/science/)

The numbers tell the quieter story. Atossa’s latest 10-Q for the quarter ended 31 March 2026 shows $37.9 million in total assets, of which $31.7 million is cash and equivalents, and $7.5 million in liabilities. Operating income was a loss of $9.9 million, net loss attributable to parent was $9.6 million, and diluted EPS stood at negative $1.11 on 8.6 million shares. Research and development spend was $4.8 million for the quarter, while capital expenditure was zero-because the company isn’t yet running factories. Cash used in operating activities was $9.6 million, matching the net loss, leaving the balance sheet in a classic “rinse and repeat” cycle: raise, burn, repeat. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1488039/000119312526266817/atos-10q_20260331.htm)

For context on the company’s ownership structure and insider stakes, the SEC’s ownership XML filings from 14 May 2026 show the current shareholder base, but they do not reveal any material changes in control or new block positions that would materially alter the dilution math. The filings are a snapshot, not a story, and they leave the central question unanswered: how close is (Z)-endoxifen to demonstrating a clear efficacy signal that can justify the next tranche of capital without forcing another dilutive round? (source: ATOS 4, https://www.sec.gov/Archives/edgar/data/1488039/000119312526224521/xslF345X06/ownership.xml)

If you want a chart, the renderer will surface the daily equity line for Atossa Therapeutics under ticker ATOS on the Nasdaq Capital Market, but the file itself contains no price levels, volumes, or technical indicators-because none of that evidence is supplied in the source pack. The market mechanism is therefore visible only through the filings and news wires; the price action is whatever the market decides, not what this report asserts. (source: SEC EDGAR index, https://www.sec.gov/edgar/browse/?CIK=1488039)

The company’s June 2026 424B5 filing explicitly states that the proceeds are intended to fund regulatory submissions and the continuation of clinical trials, including planned (Z)-endoxifen studies. Yet the same document does not quantify the probability of success or the expected timing of any FDA milestone decision, leaving investors to guess whether the next tranche arrives before or after the current cash runs low. The EVANGELINE Phase 2 trial abstract teased at ASCO 2026 is the closest thing to an evidence point, but abstracts are not endpoints. The file therefore deepens the tension: more capital is coming, but the timeline for de-risking the asset remains unknowable from the public record. (source: ATOS 424B5, https://www.sec.gov/Archives/edgar/data/1488039/000119312526268597/project_rdo_june_2026_-_.htm)